COLORADO SPRINGS, Colo., Nov. 25, 2013 /PRNewswire/ — (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development, is working with the the cannabis caucus in the U.S. House of Representatives to initiate substantial changes in 2014 in the way cannabis research and drug development can be done in this country. Working with leading exponents of cannabis drug research and development and a bi-partisan coalition in Congress, CBIS has drafted legislation as the template for these ground-breaking changes and is working with other interested parties for its passage early next year.
“We expect ground breaking changes in 2014 in our ability to conduct clinically-related drug research with cannabinoids,” said Dr. Robert Melamede, president, Cannabis Science. “We will have a definitively clearer pathway for much needed clinical research on cannabinoids next year that will allow us to determine the clinical affect of dozens of different strains of cannabis for chronic and infectious disease,” Dr. Melamede said.
The current bill supported by CBIS and others, “The Cannabinoid Scientific Research and Development Act,” authorizes cannabinoid scientific research as a legal entity and that cannabinoids as a class of drugs is a legitimate focus for scientific investigation as to their properties, effects and outcomes for chronic and infectious diseases for the Citizens of the United States of America.
It also states that, “a lack of understanding and scientific research regarding cannabinoids makes (it) impossible (for) an informed environment for physicians and consumers to make clinical choices regarding therapeutic treatments for a variety of diseases; and furthermore that “cannabis drug development research has been made almost impossible due to single source of marijuana supplied from a Federal source and the denial of research applications by the National Institute of Drug Abuse Public Health Service protocol review, a review process that exists for no other drug.”
The CBIS and supporters of cannabinoid research are asking that the procedures set up in the Randall v. U.S. that devised the current procedures for the distribution of marijuana for research and development from a single NIDA government source be removed as a step for the development of a scientifically sound research pathway and legal frame for cannabinoid clinical investigation.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and HIV related cancers such as Kaposi’s sarcoma.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
Robert Kane, CFO & Director